Elan's Response to Royalty Pharma Announcement

... the impact of the announced discontinuation of the development of bapineuzumab intravenous in mild to moderate Alzheimer's disease; failure to comply with anti-kickback, bribery and false claims laws in the United States, Europe and elsewhere; ...

http://technews.tmcnet.com/news/2013/04/15/7062857.htm